{"id":"NCT03259789","sponsor":"Theracos","briefTitle":"Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Bexagliflozin in Subjects With Type 2 Diabetes Mellitus Who Are Not Adequately Controlled by Metformin Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-28","primaryCompletion":"2019-01-23","completion":"2019-01-23","firstPosted":"2017-08-24","resultsPosted":"2021-07-07","lastUpdate":"2021-07-07"},"enrollment":351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Bexagliflozin tablets, 20 mg","otherNames":["EGT0001442, EGT0001474"]},{"type":"DRUG","name":"Bexagliflozin tablets, placebo","otherNames":[]},{"type":"DRUG","name":"Bexagliflozin tablets, 20 mg","otherNames":["EGT0001442, EGT0001474"]}],"arms":[{"label":"Bexagliflozin tablets, 20 mg; Double-Blind","type":"ACTIVE_COMPARATOR"},{"label":"Bexagliflozin tablets, Placebo; Double Blind","type":"PLACEBO_COMPARATOR"},{"label":"Bexagliflozin Tablets, 20 mg; High Glycemic Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 24 for Double-blind Group","timeFrame":"Baseline to week 24","effectByArm":[{"arm":"Double-blind Group: Bexagliflozin 20 mg","deltaMin":-1.09,"sd":0.076},{"arm":"Double-blind Group: Placebo","deltaMin":-0.56,"sd":0.075}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["United States","Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":158},"commonTop":["Nasopharyngitis","Polyuria","Diabetes mellitus inadequate control","Polydipsia","Glomerular filtration rate decreased"]}}